Separate ANDAs Are Required For Different Dosage Forms, FDA Guidance Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The draft guidance includes discussion of the Medicare Modernization Act's effect on FDA generic review processes, including application of 30-month stays and 180-day exclusivity. FDA will not amend its current definition of reference listed drugs, the guidance notes.
You may also be interested in...
FDA Guidance Will Detail Medicare Rx Law’s Effect On ANDA Reviews
The pending reference listed drug guidance will include questions & answers about the Medicare law’s Waxman/Hatch reforms, FDA Director of Regulatory Policy Dupont says. The guidance is expected “very shortly.”
FDA “Listed Drug” Definition For ANDA “Bundling” Should Maintain Current Flexibility – GPhA
Generic Pharmaceutical Association says forthcoming agency guidance should embody current practices, which allow ANDA filers to “bundle” different variations of generic products into one application.
Italy Leads European Push Into Conditional Reimbursement
Italy claims to have pushed farther into managed entry agreements than other European countries with strong clawback provisions on new drugs – particularly cancer drugs – if they don't work as well as their manufacturers claim. The financial clawbacks are supported by extensive outcome data collection across the country's twenty regions.